Members Login
ACTG Network
  • Home
  • About
    • About the ACTG
    • Leadership and Organizational Matrix
    • ACTG Committees and Centers
    • Underrepresented Populations
    • Contact the LOC
  • Clinical Trials
    • About the Clinical Trials Process
    • Active Clinical Trials
    • Clinical Trials Resources
  • Sites
  • Community
    • Global Community Advisory Board
    • Community Resources
    • They Became My Family
  • Publications
  • News
    • COVID-19
    • Press Releases
    • Media Coverage
    • Network Spotlights
    • Newsletters
  • For Researchers
    • Submit a Proposal
    • Specimen Repository Website
    • HIV Databases

University of Rochester Adult HIV Therapeutic Strategies Network CRS

Location

Box 689 , 601 Elmwood Avenue
Rochester, NY 14642
United States of America

CRS Coordinator

Christine Hurley
christine_hurley@urmc.rochester.edu
585-210-4136

CRS Leader

Michael Keefer
michael_keefer@urmc.rochester.edu
585-275-8058

Studies
  • A5128: US Genomic Sampling
  • A5345: HIV Rebound & Control Biomarkers
  • A5369: p24CE Vaccine Study
  • A5370: Anti-PD-1 Antibody in HIV-1
  • A5357: A Study of Long-Acting Cabotegravir Plus VRC01LS to Maintain Viral Suppression in HIV-1-Infected Adults
  • A5361s: Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
  • A5360: MINMON Study-Monitoring SOF/VEL in Treatment Naïve, Chronic HCV Participants
  • A5332: REPRIEVE Trial
  • A5324: A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification with Maraviroc and Dolutegravir with No Intensification or Intensification with Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV 
  • A5322: Long-Term Follow-up of Older HIV-infected Adults in the ACTG: Addressing Issues of Aging, HIV Infection and Inflammation (HAILO)
  • A5395: A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons with COVID-19
  • A5379: B-Enhancement of HBV vaccination in persons living with HIV (BEe-HIVe): Evaluation of HEPLISAV-B

Mission

The mission of the ACTG Network
is to cure HIV and reduce the
burden of disease due to HIV
and its complications, including
tuberculosis and viral hepatitis.

Useful Links

Government Resources
Clinical Trials Resources
Grants and Contracts
New Members

© ACTG. All Rights Reserved. | admin login